Search Results
Non-Hodgkin Lymphoma 3D Model
.model-icon-key-mobile{ display:none;} @media only screen and (max-width: 767px) { .model-icon-key-desktop{ display: none;} .model-icon-key-mobile{ display: block;} }This model contains the following chapters. Click the "Interact in 3D" button to begin.
- Healthy Bone Marrow
- Normal Blood Cell Production
- Proliferation of Cells and the Crowding Out of Normal Cells
- Signs and Symptoms
Insurance Inequities in Hodgkin Lymphoma Treatment and Survivorship in the Southeast
Black and Hispanic individuals diagnosed with Hodgkin lymphoma (HL) face worse survival rates across all ages. Using an innovative data source, this study will examine differences by insurance status in the receipt and quality of HL treatment in Aim 1 and care engagement and support after treatment (survivorship care) in Aim 2. Using diverse patient voices, this study will characterize and understand how patients make decisions about treatment and survivorship care by insurance type in Aim 3.Tisagenlecleucel
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of
Loncastuximab
Loncastuximab tesirine-lpyl is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Pralatrexate
Pralatrexate is FDA approved to treat people who have relapsed or refractory peripheral T-cell lymphoma. It is being studied to treat people who have other forms of lymphoma including diffuse large B-cell lymphoma.
Exploiting escape from Y-inactivation as a synthetic dependency in MYC-driven lymphoma
As a lymphoma develops it expresses genes that are normally silenced to convey a survival advantage. When these genes are on the X or Y (sex chromosomes) they may present a gender-specific therapeutic target. We have identified a gene (DDX3X in females or DDX3Y in males) that is reactivated in lymphomas such that the lymphomas cannot survive if this gene is removed. This project will develop new ways to inhibit DDX3X and Y as a novel treatment for poor-risk and aggressive lymphoma.Investigating the role of CREBBP mutations and epigenetic crosstalk in B-cell lymphoma
We seek to understand the genetic and epigenetic etiology of B-cell lymphoma and how deregulation of normal epigenetic programs perturb developmental programs and immune interactions. We approach this using a variety of genomic technologies to interrogate primary human tumors, CRISPR-engineered cell lines, patient-derived xenograft models and transgenic mouse models with different genetic lesions.Cellular and genetic drivers of Cutaneous γδ T-cell lymphomas (PCGDTL)
Primary cutaneous γδ T-cell lymphoma (PCGDTL) is a rare type of lymphoma caused by the rare types of T-cells called γδ T-cells (most T cells in our body in αβ T-cells). The disease usually shows symptoms in the skin, thus it is also considered a rare type of skin cancer. The disease is very aggressive. After diagnosis patients may die within 3 months. Only about 10% patients are alive after 5 years. However, little is known about the disease. For the last two decades, most knowledge has been generated with a handful of patient samples.
Blood Cancer Research Poised for Another ‘Banner Year’ in 2024
More than 25,000 medical professionals from across the world came together in December to discuss the latest blood cancer developments during the annual meeting of the American Society of Hematology (ASH). This annual event gives us the opportunity to think about what advances are on the horizon as LLS works to strengthen cures, care and quality of life for people with blood cancer and their families.
Glofitamab-gxbm
Glofitamab-gxbm is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.
Translating molecular profiles into treatment approaches to target disparities in lymphoma
Although many patients with diffuse large B-cell lymphoma (DLBCL) are cured with standard therapy, others will die from their disease. Survival is significantly worse for African American (AA) patients and those with Epstein- Barr virus (EBV), which is common in patients from Latin America. The reasons behind these poor outcomes are not well understood, in part because most studies of molecular features in lymphomas have not included enough patients from these racial and ethnic groups.Zanubrutinib
Zanubrutinib is indicated for the treatment of adult patients with:
Tazemetostat
Tazemetostat is a methyltransferase inhibitor indicated for the treatment of:
Relevance of ubiquitin dependent proteolysis in Diffuse Large B-cell lymphoma
The goal of this proposal is to investigate the significance of genes of the ubiquitin proteasome system (UPS) that are mutated in Diffuse Large B-cell Lymphoma (DLBCL). Our studies leverage the expertise in the molecular modeling of the UPS in the pathogenesis of DLBCL utilizing mouse models, patient derived xenotransplant (PDX) and cell lines. Our goal is the understanding of how genetic mutations contribute to disease development, progression and therapeutic outcome.Novel Immunotherapy Combinations in Relapsed, Refractory Mantle Cell Lymphoma
We are evaluating two parallel clinical trials with synergistic immunotherapies in mantle cell lymphoma (MCL), including 1) tafasitamab and lenalidomide and 2) glofitamab and lenalidomide. We will investigate how these treatments impact the MCL immune microenvironment and mediate anti-tumor immune responses, and will correlate these changes with outcome. Our goal is to develop safe, effective, and "off-the-shelf" immunotherapies to improve outcomes for patients with relapsed, refractory MCL.Detection and treatment of Adult T cell leukemia/lymphoma in the premalignant stage.
Clonally expanded T cells carrying somatic mutations circulate in the premalignant phase of Adult T cell leukemia/lymphoma (ATL). We will develop capture-sequencing of recurrent ATL-driver mutations for use as a diagnostic tool for the detection/characterization of ATL-like clones in individuals with high risk of ATL, and, in an aligned clinical study, we will test whether a novel monoclonal antibody (targeting C-C chemokine receptor 4) can eradicate these high-risk cells.2018 Nobel Prize in Physiology or Medicine: Unleashing the Immune System
The Nobel Prize in Physiology or Medicine has been awarded today to two scientists whose groundbreaking work led to the development of a class of immunotherapies called checkpoint inhibitors that work by releasing the brakes on the immune system.
Discovery and therapeutic targeting of novel mechanisms driving Double Hit Lymphomas
Double-hit lymphoma (DHL) is an aggressive form of diffuse large B-cell lymphoma (DLBCL) defined by co-occuring MYC and BCL2 rearrangements. DHL has been linked to very poor outcomes when treated with R-CHOP chemotherapy. Effective treatments to prevent treatment failure remain a critical unmet need. This proposal will develop novel, mechanism-based therapeutic regimens for DHL that overcome chemotherapy resistance and defective immune surveillance to improve outcomes.Autologous CD22 CAR T cell Therapy for the Treatment of non-Hodgkin Lymphoma
CD19 targeting chimeric antigen receptor (CAR) T cell therapies (CAR19) are effective treatments for patients with non-Hodgkin Lymphoma (NHL), however, the majority of these patients will relapse. We have now evaluated a CD22 targeting CAR T cell therapy (CAR22) in patients who have large B cell lymphoma who have relapsed after CAR19 therapy and found that this therapy is both safe and effective resulting in a high rate of durable complete responses.Development of mutant GTPase-specific degraders for peripheral T cell lymphoma treatment
This project aims to develop targeted therapies against peripheral T cell lymphoma (PTCL), a diverse group of aggressive blood cancers with poor clinical outcomes. This project is tightly relevant to cancer control and treatment, promising to advance our understanding on how blood cancers initiate and progress, and lead to new therapeutics for the treatment of peripheral T cell lymphoma (PTCL). We will develop targeted therapeutics to engage an oncogenic RHOA GTPase mutant to treat PTCL and other types of tumors with similar genetic backgrounds.CAR-T Immunotherapy Showing Positive Results
This week, positive data from a Kite Pharma CAR-T immunotherapy clinical trial was released showing that more than one-third of refractory aggressive non-Hodgkin lymphoma (NHL) patients in the study showed no signs of the disease after six months.
Since 2015, The Leukemia & Lymphoma Society has been funding this study through its collaboration with Kite Pharma, a biotechnology company focused on immunotherapy.